Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Accumulated Expenses (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Accumulated Expenses for 15 consecutive years, with $520656.0 as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 26.38% to $520656.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $520656.0, a 26.38% decrease, with the full-year FY2025 number at $2.5 million, up 245.5% from a year prior.
  • Accumulated Expenses was $520656.0 for Q4 2025 at PharmaCyte Biotech, down from $595656.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $2.5 million in Q2 2025 to a low of $27100.0 in Q4 2021.
  • A 5-year average of $619661.2 and a median of $530265.0 in 2021 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: tumbled 94.68% in 2021, then surged 1559.98% in 2022.
  • PharmaCyte Biotech's Accumulated Expenses stood at $27100.0 in 2021, then soared by 1559.98% to $449855.0 in 2022, then soared by 126.33% to $1.0 million in 2023, then tumbled by 30.54% to $707185.0 in 2024, then dropped by 26.38% to $520656.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Accumulated Expenses are $520656.0 (Q4 2025), $595656.0 (Q3 2025), and $2.5 million (Q2 2025).